Combination and summary of ATLAS dark matter searches interpreted in a 2HDM with a pseudo-scalar mediator using 139 fb−1 of s = 13 TeV pp collision data - G. Aad; B. Abbott; K. Abeling; N.J. Abicht; S.H. Abidi; A. Aboulhorma; H. Abramowicz; H. Abreu; Y. Abulaiti; A.C. Abusleme Hoffman; B.S. Acharya; C. Adam Bourdarios; et al. (Science Bulletin, 2024)

Regulation of osteogenic differentiation by the pro-inflammatory cytokines IL-1β and TNF-α: current conclusions and controversies - Qingyun Mo; Wei Zhang; Aijing Zhu; Ludvig J. Backman; Jialin Chen (Human Cell, 2022)

Solution structure and biochemical characterization of a spare part protein that restores activity to an oxygen-damaged glycyl radical enzyme - Sarah E. J. Bowman; Lindsey R. F. Backman; Rebekah E. Bjork; Mary C. Andorfer; Santiago Yori; Alessio Caruso; Collin M. Stultz; Catherine L. Drennan (JBIC Journal of Biological Inorganic Chemistry, 2019)

Voriconazole greatly increases the exposure to oral buprenorphine - Mari Fihlman; Tuija Hemmilä; Nora M. Hagelberg; Janne T. Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T. Olkkola; Teijo I. Saari (European Journal of Clinical Pharmacology, 2018)

Bleaching response of coral species in the context of assemblage response - Timothy D. Swain; Emily DuBois; Scott J. Goldberg; Vadim Backman; Luisa A. Marcelino (Coral Reefs, 2017)

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction - Mari Fihlman; Tuija Hemmilä; Nora M. Hagelberg; Kristiina Kuusniemi; Janne T. Backman; Jouko Laitila; Kari Laine; Pertti J. Neuvonen; Klaus T. Olkkola; Teijo I. Saari (European Journal of Clinical Pharmacology, 2016)

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol - Tuukka Saarikoski; Teijo I. Saari; Nora M. Hagelberg; Janne T. Backman; Pertti J. Neuvonen; Mika Scheinin; Klaus T. Olkkola; Kari Laine (European Journal of Clinical Pharmacology, 2015)

Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway - Gloria Fong; Ludvig J. Backman; Gustav Andersson; Alexander Scott; Patrik Danielson (Cell and Tissue Research, 2013)

Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations - Tiina Karonen; Jouko Laitila; Mikko Niemi; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2012)

No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid - Xiaoqiang Xiang; Juha Vakkilainen; Janne T. Backman; Pertti J. Neuvonen; Mikko Niemi (European Journal of Clinical Pharmacology, 2011)

The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast - Tiina Karonen; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2011)

Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo - Marjo J. Karjalainen; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2008)

Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine - Janne T. Backman; Marika T. Schröder; Pertti J. Neuvonen (European Journal of Clinical Pharmacology, 2008)

Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation - Marjo J. Karjalainen; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2007)

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen - Aleksi Tornio; Mikko Niemi; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2007)

The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone - Aleksi Tornio; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2006)

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone - Tiina Jaakkola; Janne T. Backman; Mikko Neuvonen; Mikko Niemi; Pertti J. Neuvonen (European Journal of Clinical Pharmacology, 2006)

Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine - Janne T. Backman; Marika T. Granfors; Pertti J. Neuvonen (European Journal of Clinical Pharmacology, 2006)

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide - Mikko Niemi; Aleksi Tornio; Marja K. Pasanen; Hanna Fredrikson; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2006)

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population - Marja K. Pasanen; Janne T. Backman; Pertti J. Neuvonen; Mikko Niemi (European Journal of Clinical Pharmacology, 2006)

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide - Lauri I. Kajosaari; Tiina Jaakkola; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2006)

Integration of soil solarization with chemical, biological and cultural control for the management of soilborne diseases of vegetables - C. Stevens; V. A. Khan; R. Rodriguez-Kabana; L. D. Ploper; P. A. Backman; D. J. Collins; J. E. Brown; M. A. Wilson; E. C. K. Igwegbe (Plant and Soil, 2003)

Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes - Xia Wen; Jun-Sheng Wang; Pertti J. Neuvonen; Janne T. Backman (European Journal of Clinical Pharmacology, 2002)

Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo - Villikka K.; Varis T.; Backman J.; Neuvonen P.; Kivistö K. (European Journal of Clinical Pharmacology, 2001)

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole - Kari T. Kivistö; Jun-Sheng Wang; Janne T. Backman; Leena Nyman; Päivi Taavitsainen; Markku Anttila; Pertti J. Neuvonen (European Journal of Clinical Pharmacology, 2001)

Effects of metronidazole on midazolam metabolism in vitro and in vivo - J.-S. Wang; J.T. Backman; K.T. Kivistö; P.J. Neuvonen (European Journal of Clinical Pharmacology, 2000)

Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life - J. J. Lilja; K. T. Kivistö; J. T. Backman; P. J. Neuvonen (European Journal of Clinical Pharmacology, 2000)

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations - T. Kantola; J. T. Backman; M. Niemi; K. T. Kivistö; P. J. Neuvonen (European Journal of Clinical Pharmacology, 2000)

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin - J. T. Backman; K. T. Kivistö; K. T. Olkkola; P. J. Neuvonen (European Journal of Clinical Pharmacology, 1998)